You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTranylcypromine
Accession NumberDB00752  (APRD00645)
TypeSmall Molecule
GroupsApproved
DescriptionA propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Structure
Thumb
Synonyms
Parnate
Tranilcipromina
Transamine
Tranylcypromin
Tranylcypromine
Tranylcyprominum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Parnatetablet, film coated10 mg/1oralCovis Pharmaceuticals Inc2013-01-14Not applicableUs
Parnatetablet10 mgoralGlaxosmithkline Inc1992-12-31Not applicableCanada
Parnatetablet, film coated10 mg/1oralConcordia Pharmaceuticals Inc.2013-01-14Not applicableUs
Tranylcypromine Sulfatetablet10 mg/1oralREMEDYREPACK INC.2014-04-01Not applicableUs
Tranylcypromine Sulfatetablet, film coated10 mg/1oralActavis Pharma, Inc.2016-02-05Not applicableUs
Tranylcypromine Sulfatetablet10 mg/1oralRising Pharmaceuticals, Inc.2012-01-09Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tranylcypromine Sulfatetablet10 mg/1oralPar Pharmaceutical, Inc.2006-06-30Not applicableUs
Tranylcypromine Sulfatetablet10 mg/1oralGolden State Medical Supply, Inc.2012-02-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
JatrosomAristo Pharma
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tranylcypromine Sulfate
ThumbNot applicableDBSALT000960
Categories
UNII3E3V44J4Z9
CAS number155-09-9
WeightAverage: 133.1903
Monoisotopic: 133.089149357
Chemical FormulaC9H11N
InChI KeyInChIKey=AELCINSCMGFISI-YGPZHTELSA-N
InChI
InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8?,9-/m1/s1
IUPAC Name
(1R)-2-phenylcyclopropan-1-amine
SMILES
N[C@@H]1CC1C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassAralkylamines
Direct ParentAralkylamines
Alternative Parents
Substituents
  • Aralkylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Hydrocarbon derivative
  • Primary amine
  • Primary aliphatic amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of major depressive episode without melancholia.
PharmacodynamicsTranylcypromine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. MAO is an enzyme that catalyzes the oxidative deamination of a number of amines, including serotonin, norepinephrine, epinephrine, and dopamine. Two isoforms of MAO, A and B, are found in the body. MAO-A is mainly found within cells located in the periphery and catalyzes the breakdown of serotonin, norepinephrine, epinephrine, dopamine and tyramine. MAO-B acts on phenylethylamine, norepinephrine, epinephrine, dopamine and tyramine, is localized extracellularly and is found predominantly in the brain. While the mechanism of MAOIs is still unclear, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. It has been postulated that depression is caused by low levels of serotonin and/or norepinephrine and that increasing serotonergic and norepinephrinergic neurotransmission results in relief of depressive symptoms. MAO A inhibition is thought to be more relevant to antidepressant activity than MAO B inhibition. Selective MAO B inhibitors, such as selegiline, have no antidepressant effects.
Mechanism of actionTranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.
Related Articles
AbsorptionInterindividual variability in absorption. May be biphasic in some individuals. Peak plasma concentrations occur in one hour following oral administration with a secondary peak occurring within 2-3 hours. Biphasic absorption may represent different rates of absorption of the stereoisomers of the drug, though additional studies are required to confirm this.
Volume of distribution

1.1-5.7 L/kg

Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life1.5-3.2 hours in patients with normal renal and hepatic function
ClearanceNot Available
ToxicityIn overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9383
Caco-2 permeable+0.7935
P-glycoprotein substrateNon-substrate0.8349
P-glycoprotein inhibitor INon-inhibitor0.9566
P-glycoprotein inhibitor IINon-inhibitor0.9899
Renal organic cation transporterNon-inhibitor0.8659
CYP450 2C9 substrateNon-substrate0.8439
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7604
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.8659
CYP450 2D6 inhibitorNon-inhibitor0.7879
CYP450 2C19 inhibitorInhibitor0.8748
CYP450 3A4 inhibitorNon-inhibitor0.9372
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6942
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6686
BiodegradationReady biodegradable0.5525
Rat acute toxicity2.4266 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9807
hERG inhibition (predictor II)Non-inhibitor0.9378
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Par pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tablet, film coatedoral10 mg/1
Tabletoral10 mg/1
Prices
Unit descriptionCostUnit
Parnate 10 mg tablet1.64USD tablet
Tranylcypromine Sulfate 10 mg tablet1.3USD tablet
Tranylcypromine sulf 10 mg tablet1.25USD tablet
Parnate 10 mg Tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point79-80 °C at 1.50E+00 mm HgNot Available
water solubility4.86E+004 mg/LNot Available
logP1.58HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility1.49 mg/mLALOGPS
logP1.5ALOGPS
logP1.34ChemAxon
logS-1.9ALOGPS
pKa (Strongest Basic)9.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity41.7 m3·mol-1ChemAxon
Polarizability15.33 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00lr-4900000000-a7221eab5a5f5d286c2aView in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Frieling H, Bleich S: Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73. [PubMed:16927039 ]
  2. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774 ]
External Links
ATC CodesN06AF04
AHFS Codes
  • 28:16.04.12
PDB Entries
FDA labelDownload (152 KB)
MSDSDownload (38.3 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineTranylcypromine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineTranylcypromine may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Tranylcypromine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with 7-Nitroindazole.
AcarboseTranylcypromine may increase the hypoglycemic activities of Acarbose.
AcebutololTranylcypromine may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Tranylcypromine.
AcepromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Tranylcypromine.
AcetophenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Tranylcypromine.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Tranylcypromine.
adipiplonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Agomelatine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Tranylcypromine.
AlbiglutideTranylcypromine may increase the hypoglycemic activities of Albiglutide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alfentanil.
AliskirenTranylcypromine may increase the hypotensive activities of Aliskiren.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Tranylcypromine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Tranylcypromine.
AlogliptinTranylcypromine may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tranylcypromine.
AlprenololTranylcypromine may increase the hypotensive activities of Alprenolol.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Tranylcypromine.
AmbrisentanTranylcypromine may increase the hypotensive activities of Ambrisentan.
AmineptineTranylcypromine may increase the serotonergic activities of Amineptine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Tranylcypromine.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Tranylcypromine.
AmisulprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amisulpride.
AmitriptylineTranylcypromine may increase the serotonergic activities of Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tranylcypromine.
AmlodipineTranylcypromine may increase the hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amobarbital.
AmoxapineTranylcypromine may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tranylcypromine.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Tranylcypromine.
AmperozideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amperozide.
AmphetamineTranylcypromine may increase the hypertensive activities of Amphetamine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Tranylcypromine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Tranylcypromine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Tranylcypromine.
ApixabanThe metabolism of Apixaban can be decreased when combined with Tranylcypromine.
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Tranylcypromine.
ApraclonidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Apraclonidine.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Tranylcypromine.
AprindineThe metabolism of Aprindine can be decreased when combined with Tranylcypromine.
ArbutamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Arbutamine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Tranylcypromine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Tranylcypromine.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tranylcypromine.
ArtemetherThe metabolism of Artemether can be decreased when combined with Tranylcypromine.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Tranylcypromine resulting in a loss in efficacy.
ArticaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Asenapine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Tranylcypromine.
AtenololTranylcypromine may increase the hypotensive activities of Atenolol.
AtomoxetineTranylcypromine may increase the central neurotoxic activities of Atomoxetine.
AtropineTranylcypromine may increase the hypertensive activities of Atropine.
AxitinibThe metabolism of Axitinib can be decreased when combined with Tranylcypromine.
AzaperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Azaperone.
AzelastineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tranylcypromine.
BaclofenThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Baclofen.
BambuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bambuterol.
BarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Barbital.
BenazeprilTranylcypromine may increase the hypotensive activities of Benazepril.
BendroflumethiazideTranylcypromine may increase the hypotensive activities of Bendroflumethiazide.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Tranylcypromine.
BenzocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benzocaine.
BenzphetamineTranylcypromine may increase the hypertensive activities of Benzphetamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Tranylcypromine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tranylcypromine.
BepridilTranylcypromine may increase the hypotensive activities of Bepridil.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Tranylcypromine.
BetaxololTranylcypromine may increase the hypotensive activities of Betaxolol.
BethanidineTranylcypromine may increase the hypotensive activities of Bethanidine.
BezafibrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bezafibrate.
BifeprunoxThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bifeprunox.
BimatoprostTranylcypromine may increase the hypotensive activities of Bimatoprost.
BisoprololTranylcypromine may increase the hypotensive activities of Bisoprolol.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Tranylcypromine.
BosentanTranylcypromine may increase the hypotensive activities of Bosentan.
BretyliumTranylcypromine may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Tranylcypromine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Tranylcypromine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
BrimonidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tranylcypromine.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Tranylcypromine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Tranylcypromine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tranylcypromine.
BrotizolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brotizolam.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Tranylcypromine.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Tranylcypromine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tranylcypromine.
BupranololTranylcypromine may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tranylcypromine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Tranylcypromine.
BupropionTranylcypromine may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tranylcypromine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Tranylcypromine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tranylcypromine.
ButacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tranylcypromine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tranylcypromine.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Tranylcypromine.
CaffeineThe metabolism of Caffeine can be decreased when combined with Tranylcypromine.
CanagliflozinTranylcypromine may increase the hypoglycemic activities of Canagliflozin.
CandesartanTranylcypromine may increase the hypotensive activities of Candesartan.
CandoxatrilTranylcypromine may increase the hypotensive activities of Candoxatril.
CaptoprilTranylcypromine may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tranylcypromine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carfentanil.
CariprazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carisoprodol.
CarteololTranylcypromine may increase the hypotensive activities of Carteolol.
CarvedilolTranylcypromine may increase the hypotensive activities of Carvedilol.
CeliprololTranylcypromine may increase the hypotensive activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Tranylcypromine.
CetirizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Tranylcypromine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Tranylcypromine.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Tranylcypromine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tranylcypromine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloroprocaine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Tranylcypromine.
ChlorothiazideTranylcypromine may increase the hypotensive activities of Chlorothiazide.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Tranylcypromine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tranylcypromine.
ChlorphentermineTranylcypromine may increase the hypertensive activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorpromazine.
ChlorpropamideTranylcypromine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorprothixene.
ChlorthalidoneTranylcypromine may increase the hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Tranylcypromine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tranylcypromine.
CilazaprilTranylcypromine may increase the hypotensive activities of Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Tranylcypromine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tranylcypromine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Tranylcypromine.
CirazolineTranylcypromine may increase the hypertensive activities of Cirazoline.
CisaprideThe metabolism of Cisapride can be decreased when combined with Tranylcypromine.
CitalopramTranylcypromine may increase the serotonergic activities of Citalopram.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Tranylcypromine.
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Tranylcypromine.
ClemastineTranylcypromine may increase the anticholinergic activities of Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Tranylcypromine.
ClenbuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clenbuterol.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Tranylcypromine.
ClidiniumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with clomethiazole.
ClomipramineTranylcypromine may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Tranylcypromine.
ClonazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clonazepam.
ClonidineTranylcypromine may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tranylcypromine.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Tranylcypromine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tranylcypromine.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Tranylcypromine.
ClozapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clozapine.
CocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Tranylcypromine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tranylcypromine.
CryptenamineTranylcypromine may increase the hypotensive activities of Cryptenamine.
CyamemazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Cyclizine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Tranylcypromine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Tranylcypromine.
CyclothiazideTranylcypromine may increase the hypotensive activities of Cyclothiazide.
CyproheptadineTranylcypromine may increase the anticholinergic activities of Cyproheptadine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tranylcypromine.
DantroleneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dantrolene.
DapagliflozinTranylcypromine may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tranylcypromine.
DapoxetineTranylcypromine may increase the serotonergic activities of Dapoxetine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Tranylcypromine.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Tranylcypromine.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Tranylcypromine.
DebrisoquinTranylcypromine may increase the hypotensive activities of Debrisoquin.
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Tranylcypromine.
deramciclaneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with deramciclane.
DeserpidineTranylcypromine may increase the hypotensive activities of Deserpidine.
DesfluraneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desflurane.
DesipramineTranylcypromine may increase the serotonergic activities of Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Tranylcypromine.
DesloratadineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Tranylcypromine.
DesvenlafaxineTranylcypromine may increase the serotonergic activities of Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dexbrompheniramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Tranylcypromine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tranylcypromine.
DexmethylphenidateTranylcypromine may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineTranylcypromine may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanTranylcypromine may increase the serotonergic activities of Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Tranylcypromine.
DextromoramideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tranylcypromine.
DezocineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diazepam.
DiazoxideTranylcypromine may increase the hypotensive activities of Diazoxide.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Tranylcypromine.
DiethylpropionTranylcypromine may increase the hypertensive activities of Diethylpropion.
DifenoxinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Difenoxin.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Tranylcypromine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tranylcypromine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tranylcypromine.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Tranylcypromine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dihydromorphine.
DiltiazemTranylcypromine may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Tranylcypromine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tranylcypromine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diphenoxylate.
DipivefrinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dipivefrin.
DisopyramideTranylcypromine may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dobutamine.
DolasetronDolasetron may increase the serotonergic activities of Tranylcypromine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Tranylcypromine.
DomperidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Domperidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Tranylcypromine.
DopamineThe metabolism of Dopamine can be decreased when combined with Tranylcypromine.
DoramectinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Doramectin.
DorzolamideTranylcypromine may increase the hypotensive activities of Dorzolamide.
DosulepinTranylcypromine may increase the serotonergic activities of Dosulepin.
DoxapramTranylcypromine may increase the hypertensive activities of Doxapram.
DoxazosinTranylcypromine may increase the hypotensive activities of Doxazosin.
DoxepinTranylcypromine may increase the serotonergic activities of Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Tranylcypromine.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Tranylcypromine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
DoxylamineTranylcypromine may increase the anticholinergic activities of Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
DronabinolThe metabolism of Dronabinol can be decreased when combined with Tranylcypromine.
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Tranylcypromine.
DroperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Drotebanol.
DroxidopaThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Droxidopa.
DulaglutideTranylcypromine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Tranylcypromine.
DuloxetineTranylcypromine may increase the serotonergic activities of Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tranylcypromine.
EcgonineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Efavirenz.
EfonidipineTranylcypromine may increase the hypotensive activities of Efonidipine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Tranylcypromine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Tranylcypromine.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Tranylcypromine.
EmpagliflozinTranylcypromine may increase the hypoglycemic activities of Empagliflozin.
EnalaprilTranylcypromine may increase the hypotensive activities of Enalapril.
EnalaprilatTranylcypromine may increase the hypotensive activities of Enalaprilat.
EncainideThe metabolism of Encainide can be decreased when combined with Tranylcypromine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Tranylcypromine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tranylcypromine.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Tranylcypromine.
EntacaponeThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Entacapone.
EphedraThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ephedra.
EpinastineThe metabolism of Epinastine can be decreased when combined with Tranylcypromine.
EpinephrineTranylcypromine may increase the hypertensive activities of Epinephrine.
EpoprostenolTranylcypromine may increase the hypotensive activities of Epoprostenol.
EprosartanTranylcypromine may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Tranylcypromine.
ErgotamineTranylcypromine may increase the hypertensive activities of Ergotamine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Tranylcypromine.
EscitalopramTranylcypromine may increase the serotonergic activities of Escitalopram.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tranylcypromine.
EsmirtazapineTranylcypromine may increase the serotonergic activities of Esmirtazapine.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Tranylcypromine.
EstazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Estazolam.
EstradiolThe metabolism of Estradiol can be decreased when combined with Tranylcypromine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tranylcypromine.
EthanolTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Tranylcypromine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tranylcypromine.
EthosuximideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl loflazepate.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Tranylcypromine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tranylcypromine.
EtidocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine.
EtoperidoneTranylcypromine may increase the serotonergic activities of Etoperidone.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Tranylcypromine.
EtorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etorphine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Tranylcypromine.
ExenatideTranylcypromine may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ezogabine.
FamotidineThe metabolism of Famotidine can be decreased when combined with Tranylcypromine.
FelbamateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Felbamate.
FelodipineTranylcypromine may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fencamfamine.
FenfluramineTranylcypromine may increase the serotonergic activities of Fenfluramine.
FenoldopamTranylcypromine may increase the hypotensive activities of Fenoldopam.
FenoterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tranylcypromine.
FexofenadineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fexofenadine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Tranylcypromine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Tranylcypromine.
FlibanserinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Tranylcypromine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tranylcypromine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flunitrazepam.
FluoxetineTranylcypromine may increase the serotonergic activities of Fluoxetine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tranylcypromine.
FlupentixolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tranylcypromine.
FluspirileneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluspirilene.
FlutamideThe metabolism of Flutamide can be decreased when combined with Tranylcypromine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Tranylcypromine.
FluvoxamineTranylcypromine may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tranylcypromine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Tranylcypromine.
FosinoprilTranylcypromine may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Tranylcypromine.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Tranylcypromine.
GabapentinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with gabapentin enacarbil.
GalantamineThe metabolism of Galantamine can be decreased when combined with Tranylcypromine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Tranylcypromine.
GliclazideTranylcypromine may increase the hypoglycemic activities of Gliclazide.
GlimepirideTranylcypromine may increase the hypoglycemic activities of Glimepiride.
GlipizideTranylcypromine may increase the hypoglycemic activities of Glipizide.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Tranylcypromine.
GlutethimideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Glutethimide.
GlyburideTranylcypromine may increase the hypoglycemic activities of Glyburide.
GranisetronGranisetron may increase the serotonergic activities of Tranylcypromine.
GranisetronThe metabolism of Granisetron can be decreased when combined with Tranylcypromine.
GuanabenzTranylcypromine may increase the hypotensive activities of Guanabenz.
GuanadrelTranylcypromine may increase the hypotensive activities of Guanadrel.
GuanethidineTranylcypromine may increase the hypotensive activities of Guanethidine.
GuanfacineTranylcypromine may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tranylcypromine.
HalazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Halazepam.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Tranylcypromine.
HaloperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Tranylcypromine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tranylcypromine.
HeroinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Heroin.
HexamethoniumTranylcypromine may increase the hypotensive activities of Hexamethonium.
HexobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hexobarbital.
HydralazineTranylcypromine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideTranylcypromine may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydrocodone.
HydroflumethiazideTranylcypromine may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideTranylcypromine may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
HydroxyzineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydroxyzine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Tranylcypromine.
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Tranylcypromine.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Tranylcypromine.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Tranylcypromine.
IloperidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Iloperidone.
ImatinibThe metabolism of Imatinib can be decreased when combined with Tranylcypromine.
ImipramineTranylcypromine may increase the serotonergic activities of Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tranylcypromine.
IndacaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indacaterol.
IndalpineTranylcypromine may increase the serotonergic activities of Indalpine.
IndapamideTranylcypromine may increase the hypotensive activities of Indapamide.
IndenololTranylcypromine may increase the hypotensive activities of Indenolol.
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Tranylcypromine.
IndoraminTranylcypromine may increase the hypotensive activities of Indoramin.
Insulin AspartTranylcypromine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirTranylcypromine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineTranylcypromine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineTranylcypromine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanTranylcypromine may increase the hypoglycemic activities of Insulin Human.
Insulin LisproTranylcypromine may increase the hypoglycemic activities of Insulin Lispro.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Tranylcypromine.
IrbesartanTranylcypromine may increase the hypotensive activities of Irbesartan.
IsocarboxazidThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoflurane.
IsomethepteneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isometheptene.
IsoprenalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoprenaline.
IsradipineTranylcypromine may increase the hypotensive activities of Isradipine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Tranylcypromine.
KetamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketobemidone.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tranylcypromine.
LabetalolTranylcypromine may increase the hypotensive activities of Labetalol.
LacidipineTranylcypromine may increase the hypotensive activities of Lacidipine.
LamotrigineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lamotrigine.
LanreotideTranylcypromine may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Tranylcypromine.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Tranylcypromine.
LatanoprostTranylcypromine may increase the hypotensive activities of Latanoprost.
LercanidipineTranylcypromine may increase the hypotensive activities of Lercanidipine.
LevetiracetamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levocetirizine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Tranylcypromine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Tranylcypromine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levomethadyl Acetate.
LevomilnacipranTranylcypromine may increase the serotonergic activities of Levomilnacipran.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Tranylcypromine.
LevonordefrinTranylcypromine may increase the hypertensive activities of Levonordefrin.
LevorphanolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Levorphanol.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Tranylcypromine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tranylcypromine.
LinezolidThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Linezolid.
LiraglutideTranylcypromine may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineTranylcypromine may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilTranylcypromine may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Tranylcypromine.
LithiumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lofentanil.
LofexidineTranylcypromine may increase the hypotensive activities of Lofexidine.
LomustineThe metabolism of Lomustine can be decreased when combined with Tranylcypromine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Tranylcypromine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Tranylcypromine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tranylcypromine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tranylcypromine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Tranylcypromine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Tranylcypromine.
LosartanTranylcypromine may increase the hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Loxapine.
Lu AA21004Tranylcypromine may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Tranylcypromine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Tranylcypromine.
LurasidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lurasidone.
MacitentanTranylcypromine may increase the hypotensive activities of Macitentan.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium Sulfate.
ManidipineTranylcypromine may increase the hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tranylcypromine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Tranylcypromine.
MecamylamineTranylcypromine may increase the hypotensive activities of Mecamylamine.
MecaserminTranylcypromine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Melperone.
MephentermineTranylcypromine may increase the hypertensive activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Tranylcypromine.
MepivacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tranylcypromine.
MequitazineTranylcypromine may increase the anticholinergic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mesoridazine.
MetaraminolTranylcypromine may increase the hypertensive activities of Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metaxalone.
MetforminTranylcypromine may increase the hypoglycemic activities of Metformin.
MethadoneThe metabolism of Methadone can be decreased when combined with Tranylcypromine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tranylcypromine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methadyl Acetate.
MethamphetamineTranylcypromine may increase the hypertensive activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tranylcypromine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methotrimeprazine.
MethoxamineTranylcypromine may increase the hypertensive activities of Methoxamine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Tranylcypromine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tranylcypromine.
MethsuximideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methsuximide.
MethyldopaThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyldopa.
Methylene blueTranylcypromine may increase the serotonergic activities of Methylene blue.
MethylphenidateTranylcypromine may increase the hypertensive activities of Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methylphenobarbital.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Tranylcypromine.
MetipranololTranylcypromine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metoclopramide.
MetolazoneTranylcypromine may increase the hypotensive activities of Metolazone.
MetoprololTranylcypromine may increase the hypotensive activities of Metoprolol.
MetyrosineTranylcypromine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Tranylcypromine.
MianserinTranylcypromine may increase the neurotoxic activities of Mianserin.
MibefradilTranylcypromine may increase the hypotensive activities of Mibefradil.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tranylcypromine.
MidodrineTranylcypromine may increase the hypertensive activities of Midodrine.
MifepristoneTranylcypromine may increase the hypoglycemic activities of Mifepristone.
MiglitolTranylcypromine may increase the hypoglycemic activities of Miglitol.
MilnacipranTranylcypromine may increase the serotonergic activities of Milnacipran.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Tranylcypromine.
MinaprineThe metabolism of Minaprine can be decreased when combined with Tranylcypromine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
MinoxidilTranylcypromine may increase the hypotensive activities of Minoxidil.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Tranylcypromine.
MirtazapineTranylcypromine may increase the central neurotoxic activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tranylcypromine.
MoclobemideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moclobemide.
MoexiprilTranylcypromine may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Morphine.
MoxonidineTranylcypromine may increase the hypotensive activities of Moxonidine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.
NabiloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nabilone.
NadololTranylcypromine may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nalbuphine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Tranylcypromine.
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Tranylcypromine.
NateglinideTranylcypromine may increase the hypoglycemic activities of Nateglinide.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Tranylcypromine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Tranylcypromine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Tranylcypromine.
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Tranylcypromine.
NetupitantThe metabolism of Netupitant can be decreased when combined with Tranylcypromine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Tranylcypromine.
NicardipineTranylcypromine may increase the hypotensive activities of Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Tranylcypromine.
NicorandilTranylcypromine may increase the hypotensive activities of Nicorandil.
NicotineThe metabolism of Nicotine can be decreased when combined with Tranylcypromine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Tranylcypromine.
NiguldipineTranylcypromine may increase the hypotensive activities of Niguldipine.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Tranylcypromine.
NilvadipineTranylcypromine may increase the hypotensive activities of Nilvadipine.
NimodipineTranylcypromine may increase the hypotensive activities of Nimodipine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Tranylcypromine.
NisoldipineTranylcypromine may increase the hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nitrazepam.
NitrendipineTranylcypromine may increase the hypotensive activities of Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Tranylcypromine.
NitroprussideTranylcypromine may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nitrous oxide.
NorepinephrineTranylcypromine may increase the hypertensive activities of Norepinephrine.
NormethadoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Normethadone.
NortriptylineTranylcypromine may increase the serotonergic activities of Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tranylcypromine.
OctreotideTranylcypromine may increase the hypoglycemic activities of Octreotide.
OlanzapineTranylcypromine may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tranylcypromine.
OlmesartanTranylcypromine may increase the hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olodaterol.
OlopatadineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olopatadine.
OmapatrilatTranylcypromine may increase the hypotensive activities of Omapatrilat.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Tranylcypromine.
OndansetronThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Tranylcypromine.
OpiumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Opium.
OrciprenalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Orciprenaline.
OrphenadrineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tranylcypromine.
OsanetantThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Osanetant.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Tranylcypromine.
OxazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxazepam.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Tranylcypromine.
OxprenololTranylcypromine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tranylcypromine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxybuprocaine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Tranylcypromine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tranylcypromine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tranylcypromine.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Tranylcypromine.
PaliperidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Paliperidone.
PalonosetronPalonosetron may increase the serotonergic activities of Tranylcypromine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Tranylcypromine.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Tranylcypromine.
ParaldehydeTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Tranylcypromine.
PargylineTranylcypromine may increase the hypotensive activities of Pargyline.
ParoxetineTranylcypromine may increase the serotonergic activities of Paroxetine.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tranylcypromine.
PasireotideTranylcypromine may increase the hypoglycemic activities of Pasireotide.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Tranylcypromine.
PenbutololTranylcypromine may increase the hypotensive activities of Penbutolol.
PentamidineTranylcypromine may increase the hypoglycemic activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tranylcypromine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tranylcypromine.
PentoliniumTranylcypromine may increase the hypotensive activities of Pentolinium.
PerampanelThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perampanel.
PergolideThe metabolism of Pergolide can be decreased when combined with Tranylcypromine.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Tranylcypromine.
PerindoprilTranylcypromine may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perphenazine.
PethidineTranylcypromine may increase the serotonergic activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tranylcypromine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Tranylcypromine.
PhenelzineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenelzine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Tranylcypromine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenobarbital.
PhenoxybenzamineTranylcypromine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenoxyethanol.
PhentermineTranylcypromine may increase the hypertensive activities of Phentermine.
PhentolamineTranylcypromine may increase the hypotensive activities of Phentolamine.
PhenylephrineTranylcypromine may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenylpropanolamine.
PhenytoinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Phenytoin.
PholcodinePholcodine may increase the serotonergic activities of Tranylcypromine.
PimozideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pimozide.
PinacidilTranylcypromine may increase the hypotensive activities of Pinacidil.
PindololTranylcypromine may increase the hypotensive activities of Pindolol.
PioglitazoneTranylcypromine may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Tranylcypromine.
PipotiazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pirbuterol.
PizotifenTranylcypromine may increase the anticholinergic activities of Pizotifen.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Tranylcypromine.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Tranylcypromine.
PolythiazideTranylcypromine may increase the hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pomalidomide.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Tranylcypromine.
PramipexoleTranylcypromine may increase the sedative activities of Pramipexole.
PramlintideTranylcypromine may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pramocaine.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Tranylcypromine.
PrazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prazepam.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Tranylcypromine.
PrazosinTranylcypromine may increase the hypotensive activities of Prazosin.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tranylcypromine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tranylcypromine.
PrimidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Primidone.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Tranylcypromine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tranylcypromine.
ProcarbazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Procarbazine.
ProcaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prochlorperazine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Tranylcypromine.
ProguanilThe metabolism of Proguanil can be decreased when combined with Tranylcypromine.
PromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Promazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Tranylcypromine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Tranylcypromine.
PropafenoneThe serum concentration of Tranylcypromine can be increased when it is combined with Propafenone.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Tranylcypromine.
ProparacaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Proparacaine.
PropericiazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propericiazine.
PropofolThe metabolism of Propofol can be decreased when combined with Tranylcypromine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tranylcypromine.
PropoxycaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Propoxycaine.
PropranololTranylcypromine may increase the hypotensive activities of Propranolol.
ProtriptylineTranylcypromine may increase the serotonergic activities of Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tranylcypromine.
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Tranylcypromine.
PSD502The risk or severity of adverse effects can be increased when Tranylcypromine is combined with PSD502.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Tranylcypromine.
QuazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Quetiapine.
QuinaprilTranylcypromine may increase the hypotensive activities of Quinapril.
QuinineTranylcypromine may increase the hypoglycemic activities of Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Tranylcypromine.
RamelteonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ramelteon.
RamiprilTranylcypromine may increase the hypotensive activities of Ramipril.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Tranylcypromine.
RasagilineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Remifentanil.
RemikirenTranylcypromine may increase the hypotensive activities of Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Remoxipride.
RepaglinideTranylcypromine may increase the hypoglycemic activities of Repaglinide.
repinotanThe metabolism of repinotan can be decreased when combined with Tranylcypromine.
RescinnamineTranylcypromine may increase the hypotensive activities of Rescinnamine.
ReserpineTranylcypromine may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tranylcypromine.
RiociguatTranylcypromine may increase the hypotensive activities of Riociguat.
RisperidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Risperidone.
RitodrineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ritodrine.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Tranylcypromine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Tranylcypromine.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Tranylcypromine.
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Tranylcypromine.
RomifidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Romifidine.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Tranylcypromine.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Tranylcypromine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tranylcypromine.
RosiglitazoneTranylcypromine may increase the hypoglycemic activities of Rosiglitazone.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Tranylcypromine.
RotigotineTranylcypromine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tranylcypromine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with S-Ethylisothiourea.
SalbutamolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salmeterol.
SaprisartanTranylcypromine may increase the hypotensive activities of Saprisartan.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Tranylcypromine.
SaxagliptinTranylcypromine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tranylcypromine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Tranylcypromine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Tranylcypromine.
SelexipagTranylcypromine may increase the hypotensive activities of Selexipag.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Tranylcypromine.
SertindoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sertindole.
SertralineTranylcypromine may increase the serotonergic activities of Sertraline.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Tranylcypromine.
SevofluraneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sevoflurane.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Tranylcypromine.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Tranylcypromine.
SitagliptinTranylcypromine may increase the hypoglycemic activities of Sitagliptin.
SitaxentanTranylcypromine may increase the hypotensive activities of Sitaxentan.
Sodium oxybateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sodium oxybate.
SparteineThe metabolism of Sparteine can be decreased when combined with Tranylcypromine.
SpiraprilTranylcypromine may increase the hypotensive activities of Spirapril.
StiripentolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tranylcypromine.
SulfadiazineTranylcypromine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleTranylcypromine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleTranylcypromine may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Tranylcypromine.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Tranylcypromine.
SunitinibTranylcypromine may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Suvorexant.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Tranylcypromine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Tranylcypromine.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Tranylcypromine.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Tranylcypromine.
TasimelteonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tasimelteon.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Tranylcypromine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Tranylcypromine.
TelmisartanTranylcypromine may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tranylcypromine.
TemocaprilTranylcypromine may increase the hypotensive activities of Temocapril.
TeniposideThe metabolism of Teniposide can be decreased when combined with Tranylcypromine.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Tranylcypromine.
TerbutalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terbutaline.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Tranylcypromine.
TerlipressinTranylcypromine may increase the hypotensive activities of Terlipressin.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Tranylcypromine.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Tranylcypromine.
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Tranylcypromine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tranylcypromine.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Tranylcypromine.
TetracaineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrodotoxin.
TetryzolineTranylcypromine may increase the hypertensive activities of Tetryzoline.
ThalidomideTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tranylcypromine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Tranylcypromine.
ThiamylalThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tranylcypromine.
ThioproperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tranylcypromine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tranylcypromine.
ThiothixeneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiagabine.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Tranylcypromine.
TianeptineTranylcypromine may increase the serotonergic activities of Tianeptine.
TiboloneTranylcypromine may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Tranylcypromine.
TicrynafenTranylcypromine may increase the hypotensive activities of Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiletamine.
TimololTranylcypromine may increase the hypotensive activities of Timolol.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Tranylcypromine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Tranylcypromine.
TizanidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tizanidine.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Tranylcypromine.
TolazamideTranylcypromine may increase the hypoglycemic activities of Tolazamide.
TolazolineTranylcypromine may increase the hypotensive activities of Tolazoline.
TolbutamideTranylcypromine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tolcapone.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Tranylcypromine.
TopiramateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Topiramate.
TorasemideTranylcypromine may increase the hypotensive activities of Torasemide.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Tranylcypromine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Tranylcypromine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tranylcypromine.
TrandolaprilTranylcypromine may increase the hypotensive activities of Trandolapril.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trans-2-Phenylcyclopropylamine.
TravoprostTranylcypromine may increase the hypotensive activities of Travoprost.
TrazodoneTranylcypromine may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Tranylcypromine.
TreprostinilTranylcypromine may increase the hypotensive activities of Treprostinil.
TriazolamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triazolam.
TrichlormethiazideTranylcypromine may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triflupromazine.
TrimazosinTranylcypromine may increase the hypotensive activities of Trimazosin.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Tranylcypromine.
TrimethaphanTranylcypromine may increase the hypotensive activities of Trimethaphan.
TrimipramineTranylcypromine may increase the serotonergic activities of Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tranylcypromine.
TriprolidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triprolidine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Tranylcypromine.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Tranylcypromine.
UnoprostoneTranylcypromine may increase the hypotensive activities of Unoprostone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tranylcypromine.
ValsartanTranylcypromine may increase the hypotensive activities of Valsartan.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Tranylcypromine.
VenlafaxineTranylcypromine may increase the serotonergic activities of Venlafaxine.
VerapamilThe metabolism of Verapamil can be decreased when combined with Tranylcypromine.
VigabatrinThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vigabatrin.
VilanterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vilanterol.
VilazodoneTranylcypromine may increase the serotonergic activities of Vilazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Tranylcypromine.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Tranylcypromine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Tranylcypromine.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Tranylcypromine.
VortioxetineTranylcypromine may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tranylcypromine.
WarfarinThe metabolism of Warfarin can be decreased when combined with Tranylcypromine.
XylazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Xylazine.
XylometazolineTranylcypromine may increase the hypotensive activities of Xylometazoline.
YohimbineThe therapeutic efficacy of Tranylcypromine can be decreased when used in combination with Yohimbine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Tranylcypromine.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Tranylcypromine.
ZaleplonThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ziconotide.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Tranylcypromine.
ZimelidineTranylcypromine may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tranylcypromine.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Tranylcypromine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Tranylcypromine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tranylcypromine.
ZonisamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zuclopenthixol.
Food Interactions
  • Avoid aged foods (chesse, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St. John's Wort.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163 ]
  3. Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010 Oct 4;482(3):216-9. doi: 10.1016/j.neulet.2010.07.039. Epub 2010 Jul 23. [PubMed:20655983 ]
  4. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol. 2006 Mar;17(2):151-9. [PubMed:16495723 ]
  5. Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87. [PubMed:15351283 ]
  6. Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40. [PubMed:15276688 ]
  7. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511 ]
  8. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774 ]
  9. Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9. [PubMed:10548268 ]
  10. Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16. [PubMed:10494892 ]
  11. Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. [PubMed:10027835 ]
  12. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. [PubMed:8749840 ]
  13. Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8. [PubMed:12504917 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. [PubMed:9829163 ]
  3. Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010 Oct 4;482(3):216-9. doi: 10.1016/j.neulet.2010.07.039. Epub 2010 Jul 23. [PubMed:20655983 ]
  4. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol. 2006 Mar;17(2):151-9. [PubMed:16495723 ]
  5. Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87. [PubMed:15351283 ]
  6. Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40. [PubMed:15276688 ]
  7. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511 ]
  8. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. [PubMed:14574774 ]
  9. Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9. [PubMed:10548268 ]
  10. Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16. [PubMed:10494892 ]
  11. Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. [PubMed:10027835 ]
  12. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. [PubMed:8749840 ]
  13. Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8. [PubMed:12504917 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Stadel R, Yang J, Nalwalk JW, Phillips JG, Hough LB: High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain. Drug Metab Dispos. 2008 Mar;36(3):614-21. Epub 2007 Dec 19. [PubMed:18094038 ]
  2. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. [PubMed:15049511 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23